Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 3/20 | 0.53 |
| ▸ | HTR7 | P34969 | 2/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6411963 | 0.85 | KMT2A (0.61) | MEN1KMT2AALDH1A1PTGS1PTGS2 | |
| SCHEMBL6416291 | 0.82 | TSHR (0.50) | MEN1KMT2AALDH1A1PTGS1PTGS2 | |
| SCHEMBL6409634 | 0.81 | ALDH1A1 (0.53) | MEN1KMT2AALDH1A1TSHRHTT | |
| SCHEMBL8355121 | 0.79 | KDM4E (0.59) | ALDH1A1PTGS1PTGS2TSHRHTR1A | |
| SCHEMBL3968107 | 0.78 | ALDH1A1 (0.77) | ALDH1A1TSHR | |
| SCHEMBL6263437 | 0.78 | ALDH1A1 (0.64) | MEN1KMT2AALDH1A1TSHRHTR1A | |
| SCHEMBL13900076 | 0.77 | F10 (0.65) | MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL13900088 | 0.76 | F10 (0.55) | MEN1KMT2A | |
| SCHEMBL9646111 | 0.76 | ALDH1A1 (0.73) | MEN1KMT2AALDH1A1HTR1AHTR7 | |
| SCHEMBL6266820 | 0.75 | ALDH1A1 (0.60) | MEN1KMT2AALDH1A1TSHRHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651602-A2 | ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS COMPRISING THE SAME AND USE THEREOF | Aventis Pharma S.A. (FR) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005009947-A2 | ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS COMPRISING THE SAME AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2005-02-03 | — | — | WO | disclosed |
| US-20050020593-A1 | Aryl-heteroaromatic compounds, compositions comprising them and use | AVENTIS PHARMA (FR) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020593-A1 | Aryl-heteroaromatic compounds, compositions comprising them and use | TUBB3, TUBB, TUBB1 | MEN1 4042/4885KMT2A 2804/4885ALDH1A1 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.